CASE STUDY
Please use the following answer the next question:
A mid-size US healthcare network has decided to develop an Al solution to detect a type of cancer that is most likely arise in adults. Specifically, the healthcare network intends to create a recognition algorithm that will perform an initial review of all imaging and then route records a radiologist for secondary review pursuant agreed-upon criteria (e.g., a confidence score below a threshold).
To date, the healthcare network has taken the following steps: defined its Al ethical principles: conducted discovery to identify the intended uses and success criteria for the system: established an Al governance committee; assembled a broad, crossfunctional team with clear roles and responsibilities; and created policies and procedures to document standards, workflows, timelines and risk thresholds during the project.
The healthcare network intends to retain a cloud provider to host the solution and a consulting firm to help develop the algorithm using the healthcare network's existing data and de-identified data that is licensed from a large US clinical research partner.
In the design phase, which of the following steps is most important in gathering the data from the clinical research partner?
All of the following are elements of establishing a global Al governance infrastructure EXCEPT?
Pursuant to the White House Executive Order of November 2023, who is responsible for creating guidelines to conduct red-teaming tests of Al systems?
A company has trained an ML model primarily using synthetic data, and now intends to use live personal data to test the model.
Which of the following is NOT a best practice apply during the testing?
What is the primary purpose of conducting ethical red-teaming on an Al system?
All of the following are included within the scope of post-deployment Al maintenance EXCEPT?
Which of the following elements of feature engineering is most important to mitigate the potential bias in an Al system?
All of the following are penalties and enforcements outlined in the EU Al Act EXCEPT?
Scenario:
An organization is developing a powerful general-purpose AI (GPAI) model that has systemic impact. The compliance team is assessing what legal obligations apply under the EU AI Act.
Under the EU AI Act, which of the following compliance actions applies only to General Purpose AI models with systemic risk?
Which of the following disclosures is NOT required for an EU organization that developed and deployed a high-risk Al system?